Answers are grounded in this paper and cite their sources.
Ollila et al address a challenging problem: can the risk for central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma be predicted better on a molecular basis? They report that most tumors with CNS recurrence have recognizable molecular features that fall into two categories: those that resemble primary CNS lymphoma and those that resemble high-grade lymphoma. These data suggest that it is time to revisit identification of patients who may benefit from CNS prophylaxis, while highlighting how challenging that is.
No takes yet. Share an insight, caveat, or question.
Ollila et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: